Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,377,903 papers from all fields of science
Search
Sign In
Create Free Account
stage III melanoma
Known as:
Stage III Skin Melanoma AJCC v6
, stage III cutaneous melanoma
, Stage III Melanoma of the Skin AJCC v6
Expand
The tumor may be any thickness, with or without ulceration (a break in the skin), and one or more of the following is true: (1) cancer has spread to…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Body tissue
Integumentary system
Melanoma Cell
Neoplastic Cell
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Adjuvant Pembrolizumab Reduces Recurrence Risk in High-Risk Resected Stage III Melanoma
D. Levitan
2018
Corpus ID: 182263264
At AACR 2018, Dr. Alexander Eggermont presented results of KEYNOTE-045/EORTC 1325-MG, in which melanoma patients with recurrence…
Expand
2014
2014
A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions.
R. Danielli
,
R. Patuzzo
,
+11 authors
M. Maio
2014
Corpus ID: 78743928
TPS9103^ Background: Preclinical studies in three different murine models of subcutaneous tumors have shown that a single…
Expand
2014
2014
ipilimumab Versus Placebo After Complete Resection Of Stage Iii Melanoma: Efficacy And Safety Results From The Eortc 18071 Phase Iii Trial : 374
A. Eggermont
,
V. Chiarion-Sileni
,
+15 authors
A. Testori
2014
Corpus ID: 79994790
2010
2010
Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel…
J. Sosman
,
J. Moon
,
+5 authors
V. Sondak
2010
Corpus ID: 74182822
8513 Background: In addition to known prognostic factors, the analysis of PB for expression of mel genes by RT-PCR (MRD) may…
Expand
2010
2010
FC13 DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics
U. Trefzer
,
T. Jouary
,
+7 authors
B. Dréno
2010
Corpus ID: 58730332
2009
2009
Stage III melanoma treated with chemotherapy after surgery during the second trimester of pregnancy.
I. Ishida
,
Y. Yamaguchi
,
+4 authors
I. Katayama
Archives of Dermatology
2009
Corpus ID: 1256258
2006
2006
Advances in Brief Polyvalent Melanoma Cell Vaccine Induces Delayed-Type Hypersensitivity and in Vitro Cellular Immune Response '
Andreas
,
Barth
,
+5 authors
Okun
2006
Corpus ID: 44272756
Patients with melanoma metastatic to distant sites or at high risk for recurrent melanoma have been treated with a polyvalent…
Expand
2004
2004
Detection of melanoma cells in the lymphatic drainage collected after lymph node dissection (LND) in stage III melanoma patients using two-marker reverse transcriptase-polymerase chain reaction (RT…
W. Ruka
,
P. Rutkowski
,
J. Kulik
,
Z. Nowecki
,
J. Siedlecki
Annals of Surgical Oncology
2004
Corpus ID: 46282147
S: PLENARY and PARALLEL SESSIONS information available preoperatively that identifies a patient population at very high risk for…
Expand
Review
2003
Review
2003
Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs
2003
Corpus ID: 27452091
Adis CommentsAVAX Technologies is developing a therapeutic melanoma vaccine [M-Vax, DNP-VACC] consisting of autologous tumour…
Expand
1976
1976
Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin, in the treatment of stage III melanoma.
Gilbert De Wasch
,
J. Bernheim
,
J. Michel
,
F. Lejeune
,
Y. Kenis
Cancer treatment reports
1976
Corpus ID: 32962983
Forty-two patients with stage III melanoma were treated with a combination of CCNU, bleomycin, and vincristine. Seventeen of 35…
Expand